This is a clinical study that will investigate two new drugs AGEN1884 and AGEN2034 in people with an advanced or metastatic solid tumour.

In the past two decades, researchers have demonstrated the importance of the immune system in controlling cancer. This has led to development of therapies that is changing how cancer is treated. The Sponsor for this trial has developed the study drugs, AGEN1884 and AGEN2034.

This study will be looking at several dose levels of the combination of the study drugs in terms of their safety and how well they are tolerated. The study will also be looking at the effectiveness of the combination of the study drugs.

The study has two parts, Part 1 and Part 2.

People in Part 1 will have been diagnosed with an advanced solid tumor (cancer) that a doctor has determined makes them eligible for this part of the study. Part 2 will include females with cervical cancer.

Both AGEN1884 and AGEN2034 activate the immune system to detect and flight the cancer cells. AGEN1884 is given every 6 weeks and AGEN2034 is given every 2 weeks, via intravenous infusion. The treatment will continue as long as there is evidence of clinical benefit, up to 24 months

You may be eligible for:

Phase 1 enrolment you:

• have advanced or metastatic solid tumours and
• have disease progression after treatment with available therapies or no standard therapy.

Phase 2 enrolment (commencing after phase 1 enrolment has been completed):

• have recurrent, unresectable, or metastatic cervical cancer and
• have relapsed after a platinum-containing doublet administered for treatment of advanced disease.

Study code: S17AGE14
When enquiring about this clinical study please quote the study code above

This clinical study is currently recruiting participants.

If you would like more information, register below or call 1800 727 874.